Fatal cardiac tamponade as the first manifestation of acute myeloid leukemia

Leptidis, John; Aloizos, Stavros; Chlorokostas, Panagiotis; Gourgiotis, Stavros

doi:10.1016/j.ajem.2014.02.045

Cited by 9 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous hematopoietic malignant disorder characterized by the uncontrolled proliferation and accumulation of immature myeloid cells in the bone marrow and peripheral blood. 1 AML is the most common form of leukemia in adults, comprising up to 12% of all leukemia in adults, with the lowest survival rate in all leukemia cases. 2 Nowadays, anthracyclinebased chemotherapy is the mainstay of the treatment approach for AML and adriamycin (ADR) is a commonly used anthracycline drug in the treatment of AML.…”

Section: Introductionmentioning

confidence: 99%

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In contrast, pericardial effusion can occur in 21% of patients with AML at initial diagnosis, but only 0.5% manifests as pericardial tamponade, [ 29 ] a condition for which only 4 documented cases can be found. [ 30 – 33 ] The average age of these 4 patients was 42 years (range, 28–73 years), of whom 3 were male and 1 was female. 2 of 4 patients died prior to any possible treatment.…”

Section: Discussionmentioning

confidence: 99%

Polyserositis as a primary clinical manifestation of CD7+ acute myelogenous leukemia with myeloid sarcoma

Wang

et al. 2020

Medicine

View full text Add to dashboard Cite

Rationale: Myeloid sarcomas (MS) are defined as rare extramedullary masses composed of immature myeloid cells. MS mostly develops in patients with acute myeloid leukemia (AML), and involves primarily the skin, soft tissues, bones, and lymph nodes. Pleura and pericardium involvement of MS are extremely uncommon. Polyserositis is also a very rare extramedullary presentation of acute myeloid leukemia (AML). Patient concerns: A 30-year-old woman with a complaint of right neck mass combined with coughing for 2 months as well as fever and systemic edema for the last 10 days, was admitted to our center on July 11, 2019. Initial positron emission tomography (PET) scan indicated systemic lymphadenopathy, bilateral pleural effusion, and pericardial effusion. Diagnosis: The initial pathological diagnosis of lymph nodes was MS. Subsequent bone marrow analysis confirmed AML. Interventions: Conventional IA induction regimen followed by high-dose cytarabine (HiDAC) regimen. Outcomes: Complete absorption of pericardial and pleural effusion after the first cycle of IA induction chemotherapy. Lessons: Polyserositis can be an extramedullary presentation of AML. Patients with polyserositis should undergo routine flow cytometric analysis. For AML with extamedullary infiltration, systemic chemotherapy should be administered in all confirmed cases.

show abstract

“…Pericardial tamponade as an initial presentation of AML is a rare entity. A thorough literature review identified only three prior reported such cases in adults [ 3 – 5 ]. The clinical presentations of these cases have been summarized in Table 1 .…”

Section: Discussionmentioning

confidence: 99%

Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature

Karmo

Hafeez

Halalau

et al. 2018

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a complex disease with a variety of presentations. A large pericardial effusion is rare, occurring in less than 0.5% of all patients with AML prior to treatment. A 34-year-old male presented with dyspnea, malaise, and weight loss. On physical exam, he was noted to be hypoxic, tachypneic, tachycardic, and hypotensive. He had cervical lymphadenopathy and jugular venous distention. His WBC count was 110 bil/L with 33% blasts. Bone marrow biopsy confirmed AML with 60% blasts. Leukemic cells were also seen in the cerebrospinal fluid on lumbar puncture. An echocardiogram revealed a large pericardial effusion causing tamponade. He underwent emergent pericardiocentesis, and malignant cells were present in the pericardial fluid. Induction therapy with standard dose cytarabine and daunorubicin was initiated, and bone marrow biopsy 14 days later showed no residual AML. This case demonstrates the importance of a thorough evaluation of each organ system when caring for a patient with AML.

show abstract

Fatal cardiac tamponade as the first manifestation of acute myeloid leukemia

Cited by 9 publications

References 6 publications

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells

Polyserositis as a primary clinical manifestation of CD7+ acute myelogenous leukemia with myeloid sarcoma

Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature

Contact Info

Product

Resources

About